(Q35997944)

11 August 2017

1 reference

title

Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus (English)

1 reference

11 August 2017

1 reference

1 reference

2

Derek LeRoith

1 reference

11 August 2017

Deirdre O Smith

1

1 reference

11 August 2017

language of work or name

1 reference

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

6

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

7-6

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Impact of the New National Cholesterol Education Program (NCEP) Guidelines on Patient Management

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Insulin resistance syndrome and obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Prevalence and trends in overweight among US children and adolescents, 1999-2000

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Serum lipids within 36 mo of delivery in women with recent gestational diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Risk factors for gestational diabetes in black population

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

A prospective study of pregravid determinants of gestational diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Insulin resistance syndrome and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

The metabolic syndrome and chronic kidney disease in U.S. adults

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Insulin and colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980050-4

7 January 2021

10.1016/S1098-3597(04)80050-4

Identifiers

DOI

1 reference

11 August 2017

1 reference